糖尿病心血管结局试验中的西班牙裔代表性。
Hispanic representation in diabetes cardiovascular outcomes trials.
机构信息
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Center for Clinical Management Research, Department of Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, United States.
出版信息
BMJ Open Diabetes Res Care. 2019 May 4;7(1):e000656. doi: 10.1136/bmjdrc-2019-000656. eCollection 2019.
Abstract
OBJECTIVE
To examine Hispanic/Latino representation in diabetes cardiovascular outcomes trials for novel antidiabetic drugs.
RESEARCH DESIGN AND METHODS
We compared Hispanic/Latino representation, age, gender and body mass index in diabetes cardiovascular outcomes trials published from January 2008 to October 2018 to Hispanic adults with diabetes in the National Health Examination and Nutrition Survey over the same time period.
RESULTS
Hispanics/Latinos comprised 18.5 % of trial subjects, which was similar to the proportion of US adults with diabetes who identify as Hispanic. Trial subjects were significantly younger, more likely to be female, and more obese than US Hispanics/Latinos. At least 10 different Latin American countries and territories were represented across the 10 trials.
CONCLUSIONS
US Hispanics/Latinos differ from subjects in diabetes cardiovascular outcomes trials, which may limit generalizability of trial results.
摘要
目的
研究新型抗糖尿病药物的糖尿病心血管结局试验中西班牙裔/拉丁裔的代表性。
研究设计和方法
我们将 2008 年 1 月至 2018 年 10 月发表的糖尿病心血管结局试验中的西班牙裔/拉丁裔代表性、年龄、性别和体重指数与同期全国健康检查和营养调查中患有糖尿病的西班牙裔成年人进行了比较。
结果
西班牙裔/拉丁裔占试验对象的 18.5%，与美国糖尿病患者中自认为是西班牙裔的比例相似。试验对象明显更年轻，女性比例更高，肥胖程度也更高。在这 10 项试验中，至少有 10 个不同的拉丁美洲国家和地区有代表参加。
结论
美国西班牙裔/拉丁裔与糖尿病心血管结局试验中的受试者不同，这可能限制了试验结果的普遍性。
相似文献
1
Hispanic representation in diabetes cardiovascular outcomes trials.糖尿病心血管结局试验中的西班牙裔代表性。
BMJ Open Diabetes Res Care. 2019 May 4;7(1):e000656. doi: 10.1136/bmjdrc-2019-000656. eCollection 2019.
2
Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).西班牙裔/拉丁裔人群中的心血管疾病风险因素：来自西班牙裔社区健康研究/拉丁裔研究（HCHS/SOL）的经验教训。
Prog Cardiovasc Dis. 2014 Nov-Dec;57(3):230-6. doi: 10.1016/j.pcad.2014.07.006. Epub 2014 Aug 2.
3
High Cholesterol Awareness, Treatment, and Control Among Hispanic/Latinos: Results From the Hispanic Community Health Study/Study of Latinos.西班牙裔/拉丁裔人群中高胆固醇的知晓、治疗与控制：来自西班牙裔社区健康研究/拉丁裔研究的结果
J Am Heart Assoc. 2015 Jun 24;4(7):e001867. doi: 10.1161/JAHA.115.001867.
4
Relationships of nativity and length of residence in the U.S. with favorable cardiovascular health among Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL).在美国，西班牙裔/拉丁裔人群的出生地及在美国居住时长与心血管健康良好之间的关系：西班牙裔社区健康研究/拉丁裔研究（HCHS/SOL）。
Prev Med. 2016 Aug;89:84-89. doi: 10.1016/j.ypmed.2016.05.013. Epub 2016 May 16.
5
Unmet needs in Hispanic/Latino patients with type 2 diabetes mellitus.西班牙语裔/拉丁裔 2 型糖尿病患者的未满足需求。
Am J Med. 2011 Oct;124(10 Suppl):S2-9. doi: 10.1016/j.amjmed.2011.07.017.
6
Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action.避免迫在眉睫的拉丁裔/西班牙裔心血管健康危机：行动呼吁。
Ethn Dis. 2007 Summer;17(3):568-73.
7
8
Diabetes and cardiovascular disease. Is there a true Hispanic paradox?糖尿病与心血管疾病。是否存在真正的西班牙裔悖论？
Rev Invest Clin. 2004 May-Jun;56(3):282-96.
9
The association of employment status with ideal cardiovascular health factors and behaviors among Hispanic/Latino adults: Findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).就业状况与西班牙裔/拉丁裔成年人理想心血管健康因素和行为的关系：来自西班牙裔社区健康研究/拉丁裔研究（HCHS/SOL）的发现。
PLoS One. 2018 Nov 27;13(11):e0207652. doi: 10.1371/journal.pone.0207652. eCollection 2018.
10
American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).美国心脏病学会/美国心脏协会（ACC/AHA）降低动脉粥样硬化性心血管疾病风险的胆固醇治疗I类指南：基于西班牙裔社区健康研究/拉丁裔研究（HCHS/SOL）结果对美国西班牙裔/拉丁裔的影响
J Am Heart Assoc. 2017 May 11;6(5):e005045. doi: 10.1161/JAHA.116.005045.
引用本文的文献
1
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial.利拉鲁肽的真实世界心血管效应：LEADER试验的可推广性分析
medRxiv. 2025 May 30:2025.05.12.25327466. doi: 10.1101/2025.05.12.25327466.
2
Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study.在哥伦比亚2型糖尿病成年患者中使用司美格鲁肽每周一次进行血糖控制和体重减轻：COLIBRI研究的结果
Diabetes Ther. 2024 Jun;15(6):1451-1460. doi: 10.1007/s13300-024-01586-7. Epub 2024 Apr 30.
3
Intensive vs. conventional blood pressure goals in older patients with type 2 diabetes: a systematic review and meta-analysis.老年 2 型糖尿病患者强化与常规血压目标值比较：系统评价和荟萃分析。
Endocrine. 2022 Oct;78(1):13-23. doi: 10.1007/s12020-022-03159-9. Epub 2022 Aug 13.
4
Educational Differences in Diabetes Mortality among Hispanics in the United States: An Epidemiological Analysis of Vital Statistics Data (1989-2018).美国西班牙裔人群糖尿病死亡率的教育差异：基于生命统计数据的流行病学分析（1989 - 2018年）
J Clin Med. 2021 Sep 29;10(19):4498. doi: 10.3390/jcm10194498.
5
Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoring.有非胰岛素治疗2型糖尿病风险或患有该疾病的成年人的血糖异常：持续葡萄糖监测的见解
EClinicalMedicine. 2021 Apr 25;35:100853. doi: 10.1016/j.eclinm.2021.100853. eCollection 2021 May.
本文引用的文献
1
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.阿必鲁肽与伴有心血管疾病的 2 型糖尿病患者的心血管结局（Harmony Outcomes）：一项双盲、随机、安慰剂对照试验。
Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.
2
The Genetic Basis of Type 2 Diabetes in Hispanics and Latin Americans: Challenges and Opportunities.西班牙裔和拉丁美洲人2型糖尿病的遗传基础：挑战与机遇
Front Public Health. 2017 Dec 11;5:329. doi: 10.3389/fpubh.2017.00329. eCollection 2017.
3
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.每周一次艾塞那肽对2型糖尿病患者心血管结局的影响。
N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.
4
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
5
Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes.2型糖尿病患者患病率及护理方面的种族和族裔差异
Clin Diabetes. 2017 Jan;35(1):66-70. doi: 10.2337/cd15-0048.
6
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
7
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
8
Relationships of nativity and length of residence in the U.S. with favorable cardiovascular health among Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL).在美国，西班牙裔/拉丁裔人群的出生地及在美国居住时长与心血管健康良好之间的关系：西班牙裔社区健康研究/拉丁裔研究（HCHS/SOL）。
Prev Med. 2016 Aug;89:84-89. doi: 10.1016/j.ypmed.2016.05.013. Epub 2016 May 16.
9
Influence of Race, Ethnicity and Social Determinants of Health on Diabetes Outcomes.种族、族裔和健康的社会决定因素对糖尿病结局的影响。
Am J Med Sci. 2016 Apr;351(4):366-73. doi: 10.1016/j.amjms.2016.01.008.
10
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.利西拉肽治疗 2 型糖尿病合并急性冠状动脉综合征患者的疗效。
N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.
Zotero 插件